[Antilipemic therapy in dyslipidemias in obese non-insulin-dependent diabetics (ONIDDM)].
There are multiple lipids anomalies on diabetes. IDDM has, because of insulin lack, raised levels of triglycerides and afferent lipoproteins. NIDDM, especially the obese one, directly linked with insulin-resistance and hyperinsulinemia, has different and complex anomalies. There is a specific type named "B phenotype" with high cardiovascular risk: raised LDL chol charged with TG and low level of HDL chol. Our study on 58 cases with NIDDM obese concluded that only 28% had high TG levels but 71.8% had low levels of HDL chol. We administered fibrates, therapeutical doses, 3 months. We made lipidograms from the beginning and after one and three months. So we proved the good effect of fibrates on lipids: rise of HDL chol., moderate effect on LDL chol. for reduced cardio-vascular risk. There were good results on glucose tolerability (improving 65.8%, p < 0.01).
Palel
G
G
Disciplina Medicină Internă de Ambulator, Facultatea de Medicină, Universitatea de Medicină şi Farmacie Gr. T. Popa, Iaşi.
Coman
A
A
Petrovanu
R
R
Ungureanu
D
D
Cojocaru
M
M
D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D002995:Clofibric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D005260:Female; D011345:Fenofibrate / Q000627:therapeutic use*; D058607:Fibric Acids; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008055:Lipids / Q000032:analysis; D008297:Male; D008875:Middle Aged; D009765:Obesity
D001786:Blood Glucose; D058607:Fibric Acids; D000960:Hypolipidemic Agents; D008055:Lipids; D002995:Clofibric Acid; C019304:ciprofibrate; D011345:Fenofibrate